Extended Data Fig. 3: Treatment duration.
From: Inhibition of lysine acetyltransferase KAT6 in ER+HER2− metastatic breast cancer: a phase 1 trial
(a) Part 1A dose escalation. (b) Part 2A PF-07248144 5 mg QD monotherapy. (c) Parts 1B and 2B PF-07248144 5 mg QD plus fulvestrant 500 mg. * All patients in part 2A who received PF-07248144 5 mg QD monotherapy and all patients in part 1B and 2B who received PF-07248144 5 mg QD plus fulvestrant 500 mg had ER + HER2− breast cancer. Patients with BC indicate patients with ER + HER2 − BC. BC, breast cancer; BOR, best of response; ER, estrogen receptor; Fulv, fulvestrant; HER2, human epidermal growth factor receptor 2; NE, not evaluable; NCSLC, non-small cell lung cancer; PC, prostate cancer; PD, progressive disease; PR, partial response; QD, once a day; SD, stable disease.
